# Endo Against Lipid Lowering Therapies Hyperandrogenism Infertility Pcos

> The guideline recommends against using lipid-lowering therapies to treat hyperandrogenism or infertility in women with polycystic ovary syndrome. Consider this recommendation when encountering a PCOS patient with infertility concerns, when considering lipid drugs for androgen excess, or when assessing inappropriate lipid therapy for reproductive symptoms.

- Skill: `dromlakhani/endo-against-lipid-lowering-therapies-hyperandrogenism-infer` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-against-lipid-lowering-therapies-hyperandrogenism-infer`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-against-lipid-lowering-therapies-hyperandrogenism-infer/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-against-lipid-lowering-therapies-hyperandrogenism-infer

---


# Avoid lipid-lowering therapies to treat hyperandrogenism or infertility in polycystic ovary syndrome

## STEP 1 — Gather Information
- Confirm PCOS diagnosis per Rotterdam criteria (oligo-ovulation, hyperandrogenism, polycystic ovaries).
- Assess presence of hyperandrogenism (e.g., hirsutism, acne, elevated androgens) or infertility concerns.
- Review menstrual history, fertility goals, and pregnancy status.
- Obtain baseline lipid panel to evaluate CVD risk.
**Action:** Proceed to step 2 if hyperandrogenism or infertility is the primary treatment target.

## STEP 2 — Rule In / Rule Out
- If the clinical goal is to treat hyperandrogenism or infertility → Rule in for avoiding lipid-lowering therapies for these indications.
- Else if the goal is CVD risk reduction → Rule out; proceed to assess CVD risk.
**Decision:** If ruling in, skip lipid-lowering therapy for hyperandrogenism/infertility and go to Step 4; if ruling out, go to Step 3.

## STEP 3 — Classify or Stratify
- Calculate 10-year ASCVD risk using Pooled Cohort Equations.
- Consider risk-enhancing factors (e.g., family history, LDL-C ≥160 mg/dL, metabolic syndrome).
- Classify risk as low (<5%), borderline (5-7.4%), intermediate (7.5-19.9%), or high (≥20%).
**Action:** If ASCVD risk indicates statin benefit (per guideline thresholds), consider lipid-lowering therapy for CVD prevention; otherwise, advise lifestyle measures only.

## STEP 4 — Decide
- If hyperandrogenism/infertility was the target: do not prescribe lipid-lowering therapy; reinforce lifestyle modifications (weight management, exercise, OCPs if appropriate) for hyperandrogenism/infertility.
- If CVD risk indicates need: prescribe appropriate lipid-lowering therapy (e.g., statin) for ASCVD prevention, ensuring contraception if of reproductive potential.
**Action:** Implement decision and document rationale.

## Clinical Guardrails / Mimics / Pitfalls
- Do not use statins or other lipid-lowering agents solely to improve androgen levels or fertility outcomes in PCOS.
- Avoid statins in pregnancy or when attempting conception due to teratogenic risk.
- Recognize that lifestyle change remains first-line for hyperandrogenism and infertility in PCOS.
- Beware of mistaking elevated LDL-C in PCOS as requiring statin therapy for reproductive symptoms.
- Monitor for muscle symptoms, hepatic enzymes, and pregnancy status if statins are used for CVD prevention.

## Concrete Clinical Example
A 28-year-old woman with PCOS presents for infertility counseling; she has hirsutism and elevated testosterone. She requests a statin to lower androgens. After confirming PCOS and infertility as the goal, lipid-lowering therapy is discouraged; instead, clomiphene citrate and lifestyle modification are initiated for ovulation induction.

**Source:** Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2020, https://doi.org/10.1210/clinem/dgaa674